← Leaderboards
Krishna Kumar
Tufts University Medford
$8,099,830
Attributed
$10,157,524
Total exposure
14
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,484,692 · 15
By mechanism
R01$4,190,287 · 2
R42$3,800,047 · 2
R41$1,840,022 · 7
S10$654,336 · 4
Top collaborators
- Martin Beinborn6 shared
Others in their field
Top investigators on “Analog”
- David Heimbrook · Leidos Biomedical Research, Inc.$196,589,777
- Constance Ann Benson · University Of California, San Diego$84,289,569
- Norman Wolmark · Nsabp Foundation, Inc.$51,982,954
- Robert Turner Schooley · University Of Colorado Denver$48,513,949
- Kenneth A Bloom · University Of Nebraska-Lincoln$46,979,168
- John Hobbs · Suny At Stony Brook$41,239,084
Research focus
AnalogPeptidesDesignGlucagon-Like Peptide 1Public Health RelevanceModificationIn VivoBiologicalPeptide HydrolasesBlood GlucosePropertyLigandsResistanceNon-Insulin-Dependent Diabetes MellitusReceptorAmino AcidsEngineeringMediatingCellsN-TerminalLaboratoriesHormonesHalf-LifeAgonist
Grant awards (29)
A Robust Platform for Design and Development of Therapeutic Peptides for Metabolic Syndrome$959,031
R42 · FY2025 · DK · contact PI
Peptide YY triagonist weight loss drugs$315,342
R41 · FY2025 · DK · contact PI
A Robust Platform for Design and Development of Therapeutic Peptides for Metabolic Syndrome$1,135,509
R42 · FY2024 · DK · contact PI
A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1$478,280
R42 · FY2023 · AG · contact PI
A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1$738,741
R42 · FY2022 · AG · contact PI
Protease Stable N-Terminally Modified Therapeutic Peptides$367,389
R41 · FY2022 · DK · contact PI
A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1$488,486
R42 · FY2021 · AG · contact PI
Triagonist Peptide Therapeutics for Neuroprotection$259,613
R41 · FY2021 · GM · contact PI
Rapid High-Fidelity Assembly of Challenging Peptide Sequences$225,000
R41 · FY2019 · GM · contact PI
Design of Protease Stable Therapeutic Peptides by Non-Perturbative Modification$222,678
R41 · FY2018 · GM · contact PI
High-Purity Peptide Libraries without Chromatographic Separation$225,000
R41 · FY2014 · ES · contact PI
Stabilization of Therapeutic Peptides by Non-Perturbative Chemical Modification$225,000
R41 · FY2014 · DK · contact PI
Fluorinated Cell Surfaces to Modulate Biological Function$438,289
R01 · FY2011 · CA · contact PI
Fluorinated Cell Surfaces to Modulate Biological Function$452,618
R01 · FY2010 · CA · contact PI
Protein Design Using Unnatural Amino Acids$289,223
R01 · FY2010 · GM · contact PI
Fluorinated Cell Surfaces to Modulate Biological Function$456,335
R01 · FY2009 · CA · contact PI
Protein Design Using Unnatural Amino Acids$292,144
R01 · FY2009 · GM · contact PI
Fluorinated Cell Surfaces to Modulate Biological Function$379,200
R01 · FY2008 · CA · contact PI
Protein Design Using Unnatural Amino Acids$292,144
R01 · FY2008 · GM · contact PI
Protein Design Using Unnatural Amino Acids$279,376
R01 · FY2007 · GM · contact PI
Ion Channel Design Using Unnatural Amino Acids$257,308
R01 · FY2006 · GM · contact PI
Ion Channel Design Using Unnatural Amino Acids$263,500
R01 · FY2005 · GM
Beckman XL-I Analytical Ultracentrifuge$327,168
S10 · FY2004 · RR
Ion Channel Design Using Unnatural Amino Acids$263,500
R01 · FY2004 · GM
ANALYTICAL ULTRACENTRIFUGE: PROTEINS: FORMATION, STRUCTURE, FUNCTION &INTERACTI$196,301
S10 · FY2004 · RR
ANALYTICAL ULTRACENTRIFUGE:PROTEIN &NEURODEGENERATIVE DIS: ALZHEIMER, PARKINSON$98,150
S10 · FY2004 · RR
ANALYTICAL ULTRACENTRIFUGE: BONE FORMATION$32,717
S10 · FY2004 · RR
Ion Channel Design Using Unnatural Amino Acids$263,500
R01 · FY2003 · GM
Ion Channel Design Using Unnatural Amino Acids$263,150
R01 · FY2002 · GM